Interventional technology firm Medtronic will consolidate its business into two operating groups, effective immediately.
One group will combine the Minneapolis-based firm's Cardiac Rhythm Disease Management (CRDM), CardioVascular, and Physio-Control businesses, while the other group will include Medtronic's Spinal and Biologics, Neuromodulation, Diabetes, and Surgical Technologies units.
As part of the organizational changes, Medtronic has promoted Chris O'Connell to vice president and group president for the Spinal and Biologics, Neuromodulation, Diabetes, and Surgical Technologies group. O'Connell was formerly president of Medtronic's Diabetes business.
Reporting to O'Connell will be Bob Blankemeyer, senior vice president and president, Surgical Technologies; Steve La Neve, senior vice president and president, Spinal and Biologics; Katie Szyman, senior vice president and president, Diabetes; and Tom Tefft, senior vice president and president, Neuromodulation.
Medtronic is conducting an external search for a new executive vice president and group president for its new CRDM, CardioVascular, and Physio-Control group.
In other executive moves, Medtronic has promoted Jean-Luc Butel to the new position of executive vice president and group president, international. Dr. Rick Kuntz, formerly senior vice president and president, Neuromodulation, has been appointed as senior vice president and chief scientific, clinical, and regulatory officer.
Related Reading
Medtronic, Abbott bury patent-dispute hatchet, July 27, 2009
Medtronic announces Teach for America grant, June 11, 2009
Veran inks deal with Medtronic, June 1, 2009
Medtronic to cut jobs by July, May 20, 2009
Medtronic touts MRI pacemaker study, May 14, 2009
Copyright © 2009 AuntMinnie.com
